These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30617087)

  • 41. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
    Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
    Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calcipotriol ointment vs. betamethasone 17-valerate ointment in the treatment of lichen amyloidosis.
    Khoo BP; Tay YK; Goh CL
    Int J Dermatol; 1999 Jul; 38(7):539-41. PubMed ID: 10440287
    [No Abstract]   [Full Text] [Related]  

  • 43. Effective topical combination therapy for treatment of lichen striatus in children: a case series and review.
    Youssef SM; Teng JM
    J Drugs Dermatol; 2012 Jul; 11(7):872-5. PubMed ID: 22777233
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cycloserine-induced lichenoid drug eruption.
    Shim JH; Kim TY; Kim HO; Kim CW
    Dermatology; 1995; 191(2):142-4. PubMed ID: 8520062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Photodynamic treatment as a promising strategy applied in lichenoid tissue reaction/interface dermatitis with moderate-to-severe dysplasia: A case report.
    Pan D; Shen Y; Zhang C; Dan H; Zeng X; Zhou Y; Luo X; Chen Q
    Photodiagnosis Photodyn Ther; 2022 Jun; 38():102814. PubMed ID: 35331958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lichenoid tissue reaction/interface dermatitis: recognition, classification, etiology, and clinicopathological overtones.
    Sehgal VN; Srivastava G; Sharma S; Sehgal S; Verma P
    Indian J Dermatol Venereol Leprol; 2011; 77(4):418-29; quiz 430. PubMed ID: 21727689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lichenoid drug eruption induced by colchicine: case report.
    An I; Demir V; Akdeniz S
    Cutan Ocul Toxicol; 2017 Jun; 36(2):199-200. PubMed ID: 27345420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
    Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
    Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous immunoglobulin-induced lichenoid dermatitis: a unique adverse reaction.
    Yockey SM; Ahmed I
    Mayo Clin Proc; 1997 Dec; 72(12):1151-2. PubMed ID: 9413297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution.
    Masterson WM; Brown AM; Al Ameri MA; Patel AB
    Cancer Treat Res Commun; 2022; 30():100506. PubMed ID: 34990901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Itch in Atopic Dermatitis Management.
    Kamata Y; Tominaga M; Takamori K
    Curr Probl Dermatol; 2016; 50():86-93. PubMed ID: 27578076
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New and emerging therapies for lichenoid dermatoses.
    Boyd AS
    Dermatol Clin; 2000 Jan; 18(1):21-9, vii. PubMed ID: 10626108
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vesicular lesions in lichen amyloidosis.
    Vasani RJ
    Indian J Dermatol Venereol Leprol; 2015; 81(6):655. PubMed ID: 26515863
    [No Abstract]   [Full Text] [Related]  

  • 54. Psoriatic Plaques After Initiation of Dupilumab Therapy.
    DeGrazia TM; Raji K; Alshamekh S; Chisolm S
    Dermatitis; 2020; 31(4):e36-e37. PubMed ID: 32665517
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclosporine in the treatment of dermatologic disease: an update.
    Lim KK; Su WP; Schroeter AL; Sabers CJ; Abraham RT; Pittelkow MR
    Mayo Clin Proc; 1996 Dec; 71(12):1182-91. PubMed ID: 8945493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
    Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
    J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypertrophic lichenoid eruption due to furosemide.
    Arias-Santiago S; Aneiros-Fernandez J; Aceituno-Madera P; Burkhardt-Perez P; Naranjo Sintes R
    Acta Derm Venereol; 2010; 90(1):78-9. PubMed ID: 20107731
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.